At Davos this year, AI was a key pillar of discussion. Increasingly, people recognize the impact it is already having on innovation and growth. I believe that we will see in the months ahead companies in all sectors proving that AI is not a speculative moment in time but a durable engine of transformation that’s fundamentally reshaping how we work.
At Sanofi, AI has shifted from experimentation to becoming a vital part of our infrastructure. It now powers our R&D decisions, our supply chain and manufacturing processes, and most importantly how we discover and develop medicines. All businesses that have implemented AI in an impactful way face challenges, such as skills gaps and uncertainty, but you move beyond that by embedding AI deeply into teams and systems. This enables AI to become a key, reliable source of sustained productivity and innovation.
The critical factor in 2026 and beyond will be enterprise-scale implementation, shifting from experimenting with AI to operationalizing it at the core of how companies work. This will be the tipping point where AI speculation ends, and where it becomes a fundamental driver of growth. As more organizations reach this stage, debates about bubbles have already given way to evidence of durable, long-term value in areas including new drugs discovered by AI, optimized supply chain and manufacturing and preventative medicine powered by new technologies.
